This study is testing two drugs, APG-115 and APG-2575, for people with T-Prolymphocytic Leukemia (T-PLL) and Non-Hodgkin Lymphoma (NHL) that has come back or not responded to previous treatments. Researchers want to see how safe these drugs are, how well they work, and how your body processes them. APG-115 works by interfering with a protein called MDM2, which can help activate a natural tumor-fighting process in your body called apoptosis (programmed cell death). You might receive APG-115 alone or in combination with APG-2575. The main goals are to find the highest safe dose for APG-115 by itself and when combined with APG-2575. To join, you must be at least 18 years old and have T-PLL or NHL that has relapsed, is refractory (not responding to treatment), or you can't take other standard therapies. The study is planned to include 78 participants, but its current recruitment status is unclear.

Study design

This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It is a Phase IIa study, designed to evaluate the drugs in a group of patients.

What's involved

APG-115 is given every other day for two weeks, followed by one week off, in repeated 21-day cycles. APG-2575 is taken by mouth every day during each 21-day cycle.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoints for determining the maximum tolerated dose are measured at 21 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.